ArticleTranslational cancer research2025
Causal relationship between hypertension and cancer: a two‑sample bidirectional Mendelian randomization study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Evidence from observational studies suggests that the association between hypertension and cancer is controversial, likely due to confounding factors and reverse causality. This study employs Mendelian randomization (MR) to investigate the causal relationship between hypertension and various cancers. Methods: We conducted two‑sample bidirectional MR analyses using genetic variants associated with hypertension (484,598 participants) and 17 site-specific cancers from various genome-wide association studies (GWAS) including the GWAS Catalog, Integrative Epidemiology Unit OpenGWAS project, and FinnGen study. GWAS data on anti-hypertensive drugs prescription were used to explore potential mechanisms. The primary analysis employed the inverse variance weighted (IVW) method, supplemented by MR-Egger, weighted median, weighted mode, and simple mode methods. Heterogeneity and pleiotropy were assessed using Cochran's Q, the MR-Egger intercept test, the MR pleiotropy residual sum and outlier test, leave-one-out analysis, funnel plots, and MR-Robust Adjusted Profile Score analysis. Genetic instruments were selected based on genome-wide significance (P<5×10 Results: We identified a potential causal relationship between hypertension and a decreased risk of gastric cancer [odds ratio (OR) =0.615, 95% confidence interval (CI): 0.415-0.912, P=0.02] and colorectal cancer (OR =0.708, 95% CI: 0.516-0.971, P=0.03). MR estimates were consistent in East Asian populations (gastric cancer, OR =0.573, P=0.01; colorectal cancer, OR =0.466, P=0.001) and directionally similar in the FinnGen cohort. Reverse MR analysis indicated an inverse association of lymphoma with hypertension risk (OR =0.992, 95% CI: 0.985-1.000, P=0.044), whereas genetic predisposition to thyroid cancer was positively associated with hypertension (OR =1.008, 95% CI: 1.002-1.013, P=0.01). Further investigation identified inverse associations between gastric cancer risk and the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) (OR =0.834, P<0.001), beta-blockers (OR =0.753, P<0.001), and calcium channel blockers (CCBs) (OR =0.794, P<0.001). Similar effects were observed for colorectal cancer with ACEI/ARB (OR =0.931, P=0.03), beta-blockers (OR =0.900, P=0.01), CCB (OR =0.912, P=0.008), and diuretics (OR =0.917, P=0.03). Conclusions: Our MR analyses suggested that genetic predisposition to hypertension was associated with a reduced risk of gastric and colorectal cancer. This inverse relationship may be mediated by biological pathways that are targeted by antihypertensive drugs, highlighting a potential mechanistic link worthy of further clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.